Skip to main content
Journal cover image

Machine learning-guided covariate selection for time-to-event models developed from a small sample of real-world patients receiving bevacizumab treatment.

Publication ,  Journal Article
Karatza, E; Papachristos, A; Sivolapenko, GB; Gonzalez, D
Published in: CPT Pharmacometrics Syst Pharmacol
October 2022

Therapeutic outcomes in patients with metastatic colorectal cancer (mCRC) receiving bevacizumab treatment are highly variable, and a reliable predictive factor is not available. Progression-free survival (PFS) and overall survival (OS) were recorded from an observational, prospective study after 5 years of follow-up, including 46 patients with mCRC receiving bevacizumab treatment. Three vascular endothelial growth factor (VEGF)-A and two intercellular adhesion molecule-1 genes polymorphisms, age, gender, weight, dosing scheme, and co-treatments were collected. Given the relatively small number of events (37 [80%] for the PFS and 26 [57%] for the OS), to study the effect of these covariates on PFS and OS, a covariate analysis was performed using statistical and supervised machine learning techniques, including Cox regression, penalized Cox regression techniques (least absolute shrinkage and selection operator [LASSO], ridge regression, and elastic net), survival trees, and survival forest. The predictive performance of each method was evaluated in bootstrapped samples, using prediction error curves and the area under the curve of the receiver operating characteristic. The LASSO penalized Cox-regression model showed the best overall performance. Nonlinear mixed effects (NLME) models were developed, and a conventional stepwise covariate search was performed. Then, covariates identified as important by the LASSO model were included in the base NLME models developed for PFS and OS, resulting in improved models as compared to those obtained with the stepwise covariate search. It was shown that having gene polymorphisms in VEGFA (rs699947 and rs1570360) and ICAM1 (rs1799969) are associated with a favorable clinical outcome in patients with mCRC receiving bevacizumab treatment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

CPT Pharmacometrics Syst Pharmacol

DOI

EISSN

2163-8306

Publication Date

October 2022

Volume

11

Issue

10

Start / End Page

1328 / 1340

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Prospective Studies
  • Machine Learning
  • Intercellular Adhesion Molecule-1
  • Humans
  • Bevacizumab
  • Antineoplastic Combined Chemotherapy Protocols
  • 3214 Pharmacology and pharmaceutical sciences
  • 3208 Medical physiology
  • 1116 Medical Physiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Karatza, E., Papachristos, A., Sivolapenko, G. B., & Gonzalez, D. (2022). Machine learning-guided covariate selection for time-to-event models developed from a small sample of real-world patients receiving bevacizumab treatment. CPT Pharmacometrics Syst Pharmacol, 11(10), 1328–1340. https://doi.org/10.1002/psp4.12848
Karatza, Eleni, Apostolos Papachristos, Gregory B. Sivolapenko, and Daniel Gonzalez. “Machine learning-guided covariate selection for time-to-event models developed from a small sample of real-world patients receiving bevacizumab treatment.CPT Pharmacometrics Syst Pharmacol 11, no. 10 (October 2022): 1328–40. https://doi.org/10.1002/psp4.12848.
Karatza E, Papachristos A, Sivolapenko GB, Gonzalez D. Machine learning-guided covariate selection for time-to-event models developed from a small sample of real-world patients receiving bevacizumab treatment. CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1328–40.
Karatza, Eleni, et al. “Machine learning-guided covariate selection for time-to-event models developed from a small sample of real-world patients receiving bevacizumab treatment.CPT Pharmacometrics Syst Pharmacol, vol. 11, no. 10, Oct. 2022, pp. 1328–40. Pubmed, doi:10.1002/psp4.12848.
Karatza E, Papachristos A, Sivolapenko GB, Gonzalez D. Machine learning-guided covariate selection for time-to-event models developed from a small sample of real-world patients receiving bevacizumab treatment. CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1328–1340.
Journal cover image

Published In

CPT Pharmacometrics Syst Pharmacol

DOI

EISSN

2163-8306

Publication Date

October 2022

Volume

11

Issue

10

Start / End Page

1328 / 1340

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Prospective Studies
  • Machine Learning
  • Intercellular Adhesion Molecule-1
  • Humans
  • Bevacizumab
  • Antineoplastic Combined Chemotherapy Protocols
  • 3214 Pharmacology and pharmaceutical sciences
  • 3208 Medical physiology
  • 1116 Medical Physiology